SQSTM1-mediated clearance of cytoplasmic mutant TARDBP/TDP-43 in the monkey brain

References

• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–133.
   PubMed Web of Science ®Google Scholar
• Chen-Plotkin AS, Lee VM, Trojanowski JQ, et al. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol. 2010;6(4):211–220.
   PubMed Web of Science ®Google Scholar
• Cohen TJ, Lee VM, Trojanowski JQ, et al. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol Med. 2011;17(11):659–667.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Nonaka T, Masuda-Suzukake M, et al. Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders. Pharmacol Ther. 2017;172:22–33.
   PubMed Web of Science ®Google Scholar
• Josephs KA, Whitwell JL, Weigand SD, et al. TDP-43 is a key player in the clinical features associated with Alzheimer’s disease. Acta Neuropathol. 2014;127(6):811–824.
   PubMed Web of Science ®Google Scholar
• McAleese KE, Walker L, Erskine D, et al. TDP-43 pathology in Alzheimer’s disease, dementia with Lewy bodies and ageing. Brain Pathol. 2016;27(4):472–479.
   PubMed Web of Science ®Google Scholar
• Buratti E, Brindisi A, Giombi M, et al. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail - An important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem. 2005;280(45):37572–37584.
   PubMed Web of Science ®Google Scholar
• Prakash A, Kumar V, Banerjee A, et al. Structural heterogeneity in RNA recognition motif 2 (RRM2) of TAR DNA-binding protein 43 (TDP-43): clue to amyotrophic lateral sclerosis. J Biomol Struct Dyn. 2020;39(1):357–367.
   PubMed Web of Science ®Google Scholar
• Freibaum BD, Chitta RK, High AA, et al. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res. 2010;9(2):1104–1120.
   PubMed Web of Science ®Google Scholar
• Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-43. Cell. 2009;136(6):1001–1004.
   PubMed Web of Science ®Google Scholar
• Polymenidou M, Lagier-Tourenne C, Hutt KR, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14(4):459–468.
   PubMed Web of Science ®Google Scholar
• Ayala YM, De Conti L, Avendano-Vazquez SE, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011;30(2):277–288.
   PubMed Web of Science ®Google Scholar
• Tollervey JR, Curk T, Rogelj B, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14(4):452–458.
   PubMed Web of Science ®Google Scholar
• Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. Journal of Biological Chemistry. 2001;276(39):36337–36343.
   PubMed Web of Science ®Google Scholar
• Tank EM, Figueroa-Romero C, Hinder LM, et al. Abnormal RNA stability in amyotrophic lateral sclerosis. Nat Commun. 2018;9(1):2845.
   PubMedGoogle Scholar
• Colombrita C, Onesto E, Megiorni F, et al. TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells. J Biol Chem. 2012;287(19):15635–15647.
   PubMed Web of Science ®Google Scholar
• Costessi L, Porro F, Iaconcig A, et al. TDP-43 regulates beta-adducin (Add2) transcript stability. RNA Biol. 2014;11(10):1280–1290.
   PubMed Web of Science ®Google Scholar
• Strong MJ, Volkening K, Hammond R, et al. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci. 2007;35(2):320–327.
   PubMed Web of Science ®Google Scholar
• Volkening K, Leystra-Lantz C, Yang W, et al. Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Res. 2009;1305:168–182.
   PubMed Web of Science ®Google Scholar
• Wang IF, Wu LS, Chang HY, et al. TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem. 2008;105(3):797–806.
   PubMed Web of Science ®Google Scholar
• Blauwendraat C, Wilke C, Simon-Sanchez J, et al. The wide genetic landscape of clinical frontotemporal dementia: systematic combined sequencing of 121 consecutive subjects. Genet Med. 2018;20(2):240–249.
   PubMed Web of Science ®Google Scholar
• Deng Z, Lim J, Wang Q, et al. ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway. Autophagy. 2020;16(5):917–931.
   PubMed Web of Science ®Google Scholar
• Deng Z, Purtell K, Lachance V, et al. Autophagy receptors and neurodegenerative diseases. Trends Cell Biol. 2017;27(7):491–504.
   PubMed Web of Science ®Google Scholar
• Cha-Molstad H, Yu JE, Feng Z, et al. p62/SQSTM1/Sequestosome-1 is an N-recognin of the N-end rule pathway which modulates autophagosome biogenesis. Nat Commun. 2017;8(1):102.
   PubMedGoogle Scholar
• Laurin N, Brown JP, Morissette J, et al. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002;70(6):1582–1588.
   PubMed Web of Science ®Google Scholar
• Fecto F, Yan J, Vemula SP, et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol. 2011;68(11):1440–1446.
   PubMedGoogle Scholar
• Rubino E, Rainero I, Chio A, et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology. 2012;79(15):1556–1562.
   PubMed Web of Science ®Google Scholar
• van der Zee J, Van Langenhove T, Kovacs GG, et al. Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathol. 2014;128(3):397–410.
   PubMed Web of Science ®Google Scholar
• Arai T, Nonaka T, Hasegawa M, et al. Neuronal and glial inclusions in frontotemporal dementia with or without motor neuron disease are immunopositive for p62. Neurosci Lett. 2003;342(1–2):41–44.
   PubMed Web of Science ®Google Scholar
• Kawakami I, Arai T, Hasegawa M, et al. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Acta Neuropathol. 2019;138(5):751–770.
   PubMed Web of Science ®Google Scholar
• Mann DM, Rollinson S, Robinson A, et al. Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun. 2013;1(1):68.
   PubMed Web of Science ®Google Scholar
• Babu JR, Geetha T, Wooten MW, et al. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem. 2005;94(1):192–203.
   PubMed Web of Science ®Google Scholar
• Ramesh Babu J, Lamar Seibenhener M, Peng J, et al. Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. J Neurochem. 2008;06(1):107–120.
   Google Scholar
• Hadano S, Mitsui S, Pan L, et al. Functional links between SQSTM1 and ALS2 in the pathogenesis of ALS: cumulative impact on the protection against mutant SOD1-mediated motor dysfunction in mice. Hum Mol Genet. 2016;25(15):3321–3340.
   PubMed Web of Science ®Google Scholar
• Tanji K, Odagiri S, Miki Y, et al. p62 deficiency enhances alpha-synuclein pathology in mice. Brain Pathol. 2015;25(5):552–564.
   PubMed Web of Science ®Google Scholar
• Doi H, Adachi H, Katsuno M, et al. p62/SQSTM1 differentially removes the toxic mutant androgen receptor via autophagy and inclusion formation in a spinal and bulbar muscular atrophy mouse model. J Neurosci. 2013;33(18):7710–7727.
   PubMed Web of Science ®Google Scholar
• Gendron TF, Rademakers R, Petrucelli L, et al. TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43. J Alzheimers Dis. 2013;33(Suppl 1):S35–45.
   PubMedGoogle Scholar
• Huang C, Tong J, Bi F, et al. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J Clin Invest. 2012;122(1):107–118.
   PubMed Web of Science ®Google Scholar
• Shan X, Chiang PM, Price DL, et al. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc Natl Acad Sci U S A. 2010;107(37):16325–16330.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Oiwa K, Murata Y, et al. ALS-linked TDP-43(M337V) knock-in mice exhibit splicing deregulation without neurodegeneration. Mol Brain. 2020;13(1). DOI:https://doi.org/10.1186/s13041-020-0550-4.
   Google Scholar
• Wegorzewska I, Bell S, Cairns NJ, et al. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2009;106(44):18809–18814.
   PubMed Web of Science ®Google Scholar
• Yan S, Wang CE, Wei W, et al. TDP-43 causes differential pathology in neuronal versus glial cells in the mouse brain. Hum Mol Genet. 2014;23(10):2678–2693.
   PubMed Web of Science ®Google Scholar
• Mitchell JC, Constable R, So E, et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. Acta Neuropathol Commun. 2015;3(1):36.
   PubMedGoogle Scholar
• Wils H, Kleinberger G, Janssens J, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2010;107(8):3858–3863.
   PubMed Web of Science ®Google Scholar
• Wang G, Yang H, Yan S, et al. Cytoplasmic mislocalization of RNA splicing factors and aberrant neuronal gene splicing in TDP-43 transgenic pig brain. Mol Neurodegener. 2015;10(1):42.
   PubMedGoogle Scholar
• Yin P, Guo XY, Yang WL, et al. Caspase-4 mediates cytoplasmic accumulation of TDP-43 in the primate brains. Acta Neuropathol. 2019;137(6):919–937.
   PubMed Web of Science ®Google Scholar
• Yin P, Bai DZ, Zhu LH, et al. Cytoplasmic TDP-43 impairs the activity of the ubiquitin-proteasome system. Exp Neurol. 2021;345:113833.
   PubMed Web of Science ®Google Scholar
• Melamed Z, Lopez-Erauskin J, Baughn MW, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22(2):180–190.
   PubMed Web of Science ®Google Scholar
• Klim JR, Williams LA, Limone F, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22(2):167–179.
   PubMed Web of Science ®Google Scholar
• Ling JP, Pletnikova O, Troncoso JC, et al. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349(6248):650–655.
   PubMed Web of Science ®Google Scholar
• Chang CK, Wu TH, Wu CY, et al. The N-terminus of TDP-43 promotes its oligomerization and enhances DNA binding affinity. Biochem Biophys Res Commun. 2012;425(2):219–224.
   PubMed Web of Science ®Google Scholar
• Mompean M, Romano V, Pantoja-Uceda D, et al. The TDP-43 N-terminal domain structure at high resolution. FEBS J. 2016;283(7):1242–1260.
   PubMed Web of Science ®Google Scholar
• Qin H, Lim LZ, Wei Y, et al. TDP-43 N terminus encodes a novel ubiquitin-like fold and its unfolded form in equilibrium that can be shifted by binding to ssDNA. Proc Natl Acad Sci U S A. 2014;111(52):18619–18624.
   PubMed Web of Science ®Google Scholar
• Komatsu M, Waguri S, Koike M, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell. 2007;131(6):1149–1163.
   PubMed Web of Science ®Google Scholar
• Ma S, Attarwala IY, Xie XQ, et al. SQSTM1/p62: a potential target for neurodegenerative disease. ACS Chem Neurosci. 2019;10(5):2094–2114.
   PubMed Web of Science ®Google Scholar
• Shin WH, Park JH, Chung KC, et al. The central regulator p62 between ubiquitin proteasome system and autophagy and its role in the mitophagy and Parkinson’s disease. BMB Rep. 2020;53(1):56–63.
   PubMed Web of Science ®Google Scholar
• Kabashi E, Valdmanis PN, Dion P, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008;40(5):572–574.
   PubMed Web of Science ®Google Scholar
• Renton AE, Chio A, Traynor BJ, et al. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17–23.
   PubMed Web of Science ®Google Scholar
• Koyama A, Sugai A, Kato T, et al. Increased cytoplasmic TARDBP mRNA in affected spinal motor neurons in ALS caused by abnormal autoregulation of TDP-43. Nucleic Acids Res. 2016;44(12):5820–5836.
   PubMed Web of Science ®Google Scholar
• White MA, Kim E, Duffy A, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21(4):552–563.
   PubMed Web of Science ®Google Scholar
• Gitcho MA, Bigio EH, Mishra M, et al. TARDBP 3ʹ-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol. 2009;118(5):633–645.
   PubMed Web of Science ®Google Scholar
• Swarup V, Phaneuf D, Dupre N, et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kappaB-mediated pathogenic pathways. J Exp Med. 2011;208(12):2429–2447.
   PubMed Web of Science ®Google Scholar
• Uchida A, Sasaguri H, Kimura N, et al. Non-human primate model of amyotrophic lateral sclerosis with cytoplasmic mislocalization of TDP-43. Brain. 2012;135(Pt 3):833–846.
   PubMedGoogle Scholar
• Brady OA, Meng P, Zheng Y, et al. Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. J Neurochem. 2011;116(2):248–259.
   PubMed Web of Science ®Google Scholar
• Tanji K, Zhang HX, Mori F, et al. p62/sequestosome 1 binds to TDP-43 in brains with frontotemporal lobar degeneration with TDP-43 inclusions. J Neurosci Res. 2012;90(10):2034–2042.
   PubMed Web of Science ®Google Scholar
• Gal J, Strom AL, Kilty R, et al. p62 accumulates and enhances aggregate formation in model systems of familial amyotrophic lateral sclerosis. J Biol Chem. 2007;282(15):11068–11077.
   PubMed Web of Science ®Google Scholar
• Zatloukal K, Stumptner C, Fuchsbichler A, et al. p62 is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol. 2002;160(1):255–263.
   PubMed Web of Science ®Google Scholar
• Kumar S, Phaneuf D, Cordeau P, et al. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD. Mol Neurodegener. 2021;16(1):1.
   PubMed Web of Science ®Google Scholar
• Ormeno F, Hormazabal J, Moreno J, et al. Chaperone Mediated Autophagy Degrades TDP-43 Protein and Is Affected by TDP-43 Aggregation. Front Mol Neurosci. 2020;13:19.
   PubMed Web of Science ®Google Scholar
• Jackson LK, Lin W-L, Miriyala S, et al. p62 pathology model in the rat substantia nigra with filamentous inclusions and progressive neurodegeneration. PLoS One. 2017;12(1):e0169291.
   PubMed Web of Science ®Google Scholar
• Mitsui S, Otomo A, Nozaki M, et al. Systemic over expression of SQSTM1/p62 accelerates disease onset in a SOD1H46R-expressing ALS mouse model. Mol Brain. 2018;11(1):30.
   PubMedGoogle Scholar
• Seibenhener ML, Zhao T, Yf D, et al. Behavioral effects of SQSTM1/p62 overexpression in mice: support for a mitochondrial role in depression and anxiety. Behav Brain Res. 2013;248:94–103.
   PubMed Web of Science ®Google Scholar
• Aparicio R, Rana A, Walker DW, et al. Upregulation of the autophagy adaptor p62/SQSTM1 prolongs health and lifespan in middle-aged Drosophila. Cell Rep. 2019;28(4):1029–1040.e5.
   PubMed Web of Science ®Google Scholar
• Du YF, Wooten MC, Gearing M, et al. Age-associated oxidative damage to the p62 promoter: implications for Alzheimer disease. Free Radic Biol Med. 2009;46(4):492–501.
   PubMed Web of Science ®Google Scholar